AEON Net Debt from 2010 to 2026

AEON Stock   1.09  0.01  0.91%   
AEON Biopharma Net Debt yearly trend continues to be very stable with very little volatility. Net Debt is likely to drop to about 11.1 M. Net Debt is the total debt of AEON Biopharma minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2010-12-31
Previous Quarter
11.6 M
Current Value
11.1 M
Quarterly Volatility
29.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AEON Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AEON Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 0.0 or Depreciation And Amortization of 82.9 K, as well as many indicators such as Price To Sales Ratio of 21.27, Dividend Yield of 0.0 or Days Sales Outstanding of 23.22. AEON financial statements analysis is a perfect complement when working with AEON Biopharma Valuation or Volatility modules.
  
Build AI portfolio with AEON Stock
Check out the analysis of AEON Biopharma Correlation against competitors.
To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.

Latest AEON Biopharma's Net Debt Growth Pattern

Below is the plot of the Net Debt of AEON Biopharma over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. AEON Biopharma's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AEON Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Very volatile
   Net Debt   
       Timeline  

AEON Net Debt Regression Statistics

Arithmetic Mean30,740,365
Coefficient Of Variation96.87
Mean Deviation19,214,106
Median23,627,000
Standard Deviation29,777,960
Sample Variance886.7T
Range126.7M
R-Value0.1
Mean Square Error937T
R-Squared0.01
Significance0.71
Slope570,549
Total Sum of Squares14187.6T

AEON Net Debt History

202611.1 M
202511.6 M
202412.9 M
2023-4.9 M
2022121.8 M
202181.8 M
202052 M

Other Fundumenentals of AEON Biopharma

AEON Biopharma Net Debt component correlations

0.440.99-0.260.88-0.77-0.430.34-0.840.51-0.81.00.510.960.030.510.52
0.440.43-0.840.56-0.24-0.9-0.7-0.110.95-0.040.44-0.470.57-0.67-0.47-0.26
0.990.43-0.250.93-0.82-0.360.34-0.810.51-0.860.990.540.97-0.020.540.51
-0.26-0.84-0.25-0.360.280.840.660.03-0.64-0.04-0.260.65-0.460.860.650.21
0.880.560.93-0.36-0.76-0.370.11-0.60.65-0.790.880.370.93-0.210.370.31
-0.77-0.24-0.820.28-0.760.14-0.370.76-0.210.89-0.77-0.48-0.840.26-0.48-0.48
-0.43-0.9-0.360.84-0.370.140.590.15-0.79-0.1-0.430.51-0.50.530.510.21
0.34-0.70.340.660.11-0.370.59-0.57-0.6-0.610.340.90.180.710.90.71
-0.84-0.11-0.810.03-0.60.760.15-0.57-0.150.81-0.84-0.64-0.77-0.2-0.64-0.74
0.510.950.51-0.640.65-0.21-0.79-0.6-0.15-0.120.51-0.280.59-0.46-0.28-0.23
-0.8-0.04-0.86-0.04-0.790.89-0.1-0.610.81-0.12-0.8-0.76-0.8-0.07-0.76-0.73
1.00.440.99-0.260.88-0.77-0.430.34-0.840.51-0.80.510.960.030.510.53
0.51-0.470.540.650.37-0.480.510.9-0.64-0.28-0.760.510.350.671.00.68
0.960.570.97-0.460.93-0.84-0.50.18-0.770.59-0.80.960.35-0.230.350.45
0.03-0.67-0.020.86-0.210.260.530.71-0.2-0.46-0.070.030.67-0.230.670.3
0.51-0.470.540.650.37-0.480.510.9-0.64-0.28-0.760.511.00.350.670.68
0.52-0.260.510.210.31-0.480.210.71-0.74-0.23-0.730.530.680.450.30.68
Click cells to compare fundamentals

About AEON Biopharma Financial Statements

AEON Biopharma investors utilize fundamental indicators, such as Net Debt, to predict how AEON Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt11.6 M11.1 M
Net Debt To EBITDA(0.42)(0.44)

Pair Trading with AEON Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AEON Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AEON Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against AEON Stock

  0.68MMM 3M Company Earnings Call This WeekPairCorr
  0.57IBM International BusinessPairCorr
  0.51KO Coca Cola Aggressive PushPairCorr
  0.43CSCO Cisco SystemsPairCorr
  0.39BOF BranchOut Food CommonPairCorr
The ability to find closely correlated positions to AEON Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AEON Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AEON Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AEON Biopharma to buy it.
The correlation of AEON Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AEON Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AEON Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AEON Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AEON Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AEON Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aeon Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aeon Biopharma Stock:
Check out the analysis of AEON Biopharma Correlation against competitors.
To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AEON Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.91)
Return On Assets
(1.29)
The market value of AEON Biopharma is measured differently than its book value, which is the value of AEON that is recorded on the company's balance sheet. Investors also form their own opinion of AEON Biopharma's value that differs from its market value or its book value, called intrinsic value, which is AEON Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AEON Biopharma's market value can be influenced by many factors that don't directly affect AEON Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AEON Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if AEON Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AEON Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.